Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2009

View Archived Issues

Ex vivo IL-10 gene therapy correlates with functional repair of lung transplants

CH-5137291evaluated in preclinical models of castration-resistant prostate cancer

E-3810 exhibits potent antiangiogenic activity in preclinical studies

Favorable safety and lipid profiles with anacetrapib therapy in hyperlipidemia

Pioglitazone slows atherosclerosis progression in type 2 diabetes patients

Vasopressin V1a and V1b receptor antagonists reported by sanofi-aventis

Schering-Plough claims A2A receptor antagonists for the treatment of PD

Novel histamine receptor modulators in early development at Medivation

5-HT, DA and NE reuptake inhibitors disclosed by GSK for the treatment of anxiety

Vertex is developing ABC transporter modulators for the treatment of cystic fibrosis

Advanced BioHealing initiates prospective clinical trial for venous leg ulcers

Alkermes initiates phase II trial of ALKS-33 for alcohol dependence

Anacor starts phase I trial of AN-3365 for Gram-negative infections

Albireo presents clinical data on A-3309 in chronic idiopathic constipation

Pluristem Therapeutics reports 3-month follow-up data for PLX-PAD

Vivus reports results from phase III avanafil study in erectile dysfunction

Genzyme reports results from phase II/III trial of GENZ-644470 in hyperphosphatemia

Asterand to acquire BioSeek

Biocompatibles acquires Astron Clinica's inventory and intellectual property assets

FDA issues complete response to Genentech and Biogen's applications for rituximab in CLL

FDA committee votes that data for Prevnar 13 vaccine support safety and effectiveness

Sangamo presents update on phase I safety study of SB-728-T for HIV/AIDS

Chugai files for additional indication for Epogin in Japan

deCODE genetics files for bankruptcy in the U.S.

ImmuPharma reports final results from phase IIb trial of Lupuzor in SLE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...